Long-acting insulin combined with GLP-1 injections (once daily): Some people with type 2 diabetes use a single daily shot that includes a basal insulin and a GLP-1 medication, such as insulin glargine/lixisenatide (SOLIQUA 100/33) or insulin degludec/liraglutide (XULTOPHY 100/3.6)
Then, in September, the Trump Administration launched a crackdown on deceptive direct-to-consumer drug advertising, resulting in the FDA publishing over 55 warning letters to online sellers of compounded versions of GLP-1 medications that called for the removal of false and misleading promotional statements, claims of clinically proven weight-loss treatments, and using the words FDA-approved in advertising copy
doi: 10.1016/S2213-8587(15)00468-4
Interestingly, several alterations in intra-pancreatic actions of GIP have been found in subjects affected by T2DM
However, recent FDA decisions have removed these medications from the list of substances eligible for compounding, meaning that compounded semaglutide and compounded tirzepatide are no longer generally available